T he objective of HIV treatment is to suppress viral replication, and currently more than 20 different drugs have been approved to treat HIV. 1 Shortly after antiretroviral drugs were in clinical trial, drug resistance-associated mutations were first described. 2 HIV drug resistance has since been described for every active drug 3 and drug resistance testing has been incorporated as part of standard clinical management and clinical trial design. 4 In the course of a clinical study to assess the treatment of protease-resistant virus we discovered a previously unreported three base insert in HIV-1 clade B protease (PR) simultaneously with a six base insert in reverse transcriptase (RT) (GenBank accession number FJ159426).
HIV RNA was extracted, reverse transcribed, and the polymerase (pol) gene was amplified according to the manufacturer's instructions using the ViroSeq HIV-1 Genotyping System Version 2.0 (Celera Diagnostics, Foster City, CA). Sequence data were analyzed using ViroSeq Version 2.6 Sequence Analysis Software (Celera Diagnostics).
The six nucleotide insert ( Fig. 1A) has been described previously and is known as a T69S þ XX insertion. 5 These inserts usually have a ''T''-to-''S'' point mutation at codon 69 and then a two amino acid insertion added to the functional protein.
The proposed mechanism of decreasing susceptibility to ART by this insertion is to stall or to cause the slippage of RT during reverse transcription. 6 Virus isolates containing these inser-tions have reduced susceptibility to all nucleoside and nucleotide RT inhibitors. 7 Stalling or slippage has also been hypothesized to be the mechanism behind the generation of PR inserts. Several PR insert strains have been identified both with and without major PR resistance mutations, although these PR inserts have not been shown to directly contribute to decreased susceptibility to protease inhibitors (PI). 8 The insert we describe ( Fig.1B) has not yet been evaluated with sitedirected mutants with and without the associated PI resistance mutations for impact on PI susceptibility in vitro. This insert, however, was identified in the setting of extensive, prolonged, and intermittent ART pressure (Fig. 2) . The antiretroviral susceptibility profiles of the viruses with these inserts using the Monogram Phenosense assay are shown in Table 1 .
To model the function of the described PR insert, we generated superimposed computer models of PR with or without our specific insert (Fig. 3) . The close proximity of the one codon insert to the functional binding cleft of the PR homodimer could impact drug susceptibility, since the morphology and nature of the binding cleft may be altered by the addition of amino acids extending near or into the binding site leading to decreased PI binding. 9 Further in vitro characterization of this novel PR insert with and without corresponding PR mutations associated with decreased susceptibility to PI still need to be evaluated.
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